Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Should we move to a genomic classification of neutrophilic myeloid neoplasms?
Carreño-Tarragona G, Álvarez-Larrán A, Hernández-Boluda JC, Ayala R, Cross NCP. Carreño-Tarragona G, et al. Among authors: ayala r. Blood Adv. 2023 Nov 14;7(21):6705-6706. doi: 10.1182/bloodadvances.2023011103. Blood Adv. 2023. PMID: 37672387 Free PMC article. No abstract available.
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larrán A, Gómez M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Hernández-Boluda JC, et al. Among authors: ayala r. Ann Hematol. 2015 Jun;94(6):911-8. doi: 10.1007/s00277-015-2330-2. Epub 2015 Feb 14. Ann Hematol. 2015. PMID: 25680896
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Alvarez-Larrán A, et al. Among authors: ayala r. Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12. Haematologica. 2016. PMID: 27175028 Free PMC article.
Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Rodríguez-García A, Morales ML, Garrido-García V, García-Baquero I, Leivas A, Carreño-Tarragona G, Sánchez R, Arenas A, Cedena T, Ayala RM, Bautista JM, Martínez-López J, Linares M. Rodríguez-García A, et al. Among authors: ayala rm. Antioxidants (Basel). 2019 Oct 24;8(11):508. doi: 10.3390/antiox8110508. Antioxidants (Basel). 2019. PMID: 31652983 Free PMC article.
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Pastor-Galán I, et al. Among authors: ayala r. Med Clin (Barc). 2020 Aug 28;155(4):152-158. doi: 10.1016/j.medcli.2019.11.007. Epub 2020 Jan 21. Med Clin (Barc). 2020. PMID: 31980217 English, Spanish.
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernandez-Rodriguez C, Luño E, García Hernandez C, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boqué C, García-Gutierrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de Los Reyes-García AM, Besses C, Vicente V, Alvarez-Larrán A, Teruel-Montoya R, González-Conejero R, Martínez C; GEMFIN Group. Ferrer-Marín F, et al. Among authors: ayala r. Leukemia. 2020 Oct;34(10):2648-2659. doi: 10.1038/s41375-020-0767-3. Epub 2020 Feb 27. Leukemia. 2020. PMID: 32107471
Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, Paciello ML, Zafra D, Garcia-Sanchez C, Villegas C, Cuellar C, Carreño-Tarragona G, Zamanillo I, Poza M, Iñiguez R, Gutierrez X, Alonso R, Rodríguez A, Folgueira MD, Delgado R, Ferrari JM, Lizasoain M, Aguado JM, Ayala R, Martinez-Lopez J, Calbacho M. Sanchez-Pina JM, et al. Among authors: ayala r. Eur J Haematol. 2020 Nov;105(5):597-607. doi: 10.1111/ejh.13493. Epub 2020 Aug 11. Eur J Haematol. 2020. PMID: 32710500
Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E, Rapado I, Luz Morales M, Carreño-Tarragona G, Martinez-Sanchez P, Gutierrez X, Sáchez Pina JM, Linares M, Gallardo M, Martinez-López J, Ayala R. Onecha E, et al. Among authors: ayala r. Haematologica. 2021 Sep 1;106(9):2325-2333. doi: 10.3324/haematol.2020.254623. Haematologica. 2021. PMID: 32732356 Free PMC article.
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C, Paiva B, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Villar S, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Montesinos P. Simoes C, et al. Among authors: ayala r. Blood Adv. 2021 Feb 9;5(3):760-770. doi: 10.1182/bloodadvances.2020003195. Blood Adv. 2021. PMID: 33560390 Free PMC article. Clinical Trial.
A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline.
Carreño-Tarragona G, Varghese LN, Sebastián E, Gálvez E, Marín-Sánchez A, López-Muñoz N, Nam-Cha S, Martínez-López J, Constantinescu SN, Sevilla J, Ayala R. Carreño-Tarragona G, et al. Among authors: ayala r. Leukemia. 2021 Nov;35(11):3295-3298. doi: 10.1038/s41375-021-01239-9. Epub 2021 Apr 12. Leukemia. 2021. PMID: 33846542 No abstract available.
354 results